Breakthrough Early Stage Cancer Detection System
VRS: TSX-V
Company Highlights
• Detects melanoma with 100% accuracyvs. 33.8% for primary clinical diagnosis
• Developed by BC Cancer Agency and UBC
• Patented technology
• Exclusively licensed to T-Ray Science
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers.
Fox News: Verisante CEO Thomas Braun discusses melanoma / skin cancer detection technology
Stock Information
